I-Mab Newsroom

H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8

Futu NewsNov 15 20:33

I-MAB Receives Buy Rating as Uliledlimab and Givastomig Show Promising Clinical Progress

TipRanksNov 15 19:37

HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target

BenzingaNov 15 19:31

I-MAB Analyst Ratings

BenzingaNov 15 19:30

H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8

Futu NewsSep 18 20:31

Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)

TipRanksSep 18 20:22

I-MAB Analyst Ratings

BenzingaAug 29 19:55

HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target

BenzingaAug 29 19:55

I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline

TipRanksApr 12 18:10

Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.

Zhitong FinanceApr 12 18:10

I-MAB Analyst Ratings

BenzingaApr 12 18:05

Needham Reiterates Buy on I-MAB, Maintains $6 Price Target

BenzingaApr 12 18:05

I-MAB Analyst Ratings

BenzingaMar 18 18:45

Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)

TipRanksMar 18 18:25

I-MAB Analyst Ratings

BenzingaMar 15 21:30

Needham Maintains Buy on I-MAB, Lowers Price Target to $6

BenzingaMar 15 21:30

I-MAB Buy Rating: Strategic Pivot to U.S. Market and Promising Pipeline

TipRanksFeb 12 21:18

I-MAB Analyst Ratings

BenzingaFeb 9 04:10

Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)

TipRanksFeb 9 04:10

Needham Maintains Buy on I-MAB, Lowers Price Target to $23

BenzingaSep 25, 2023 17:57